Editorially Independent content supported with advertising by Genentech
Priya Sharma Vakharia, MD; Joseph M. Coney, MD; and Yasha S. Modi, MD
Show Description +
Two newly approved anti-VEGF agents—faricimab (Vabysmo, Genentech/Roche) and aflibercept 8 mg (Eylea HD, Regeneron)—recently entered the clinic. Priya Sharma Vakharia, MD; Joseph M. Coney, MD; and Yasha S. Modi, MD, discuss how they might use these treatment options in practice, review how to switch patients from legacy treatments to newer therapies, and examine how the pivotal study data for these two agents affect their clinical decision-making.
Posted: 1/15/2024
Priya Sharma Vakharia, MD; Joseph M. Coney, MD; and Yasha S. Modi, MD
Two newly approved anti-VEGF agents—faricimab (Vabysmo, Genentech/Roche) and aflibercept 8 mg (Eylea HD, Regeneron)—recently entered the clinic. Priya Sharma Vakharia, MD; Joseph M. Coney, MD; and Yasha S. Modi, MD, discuss how they might use these treatment options in practice, review how to switch patients from legacy treatments to newer therapies, and examine how the pivotal study data for these two agents affect their clinical decision-making.
Posted: 1/15/2024
Please log in to leave a comment.